Skip to main content

In 18 clinical studies of various formulations of topical Clindamycin Phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

Number of Patients Reporting Events

Treatment Emergent
Adverse Event
Solution
n=553 (%)
Gel
n=148 (%)
Lotion
n=160 (%)
Burning 62 (11) 15 (10) 17 (11)
Itching 36 ( 7 ) 15 (10) 17 (11)
Burning/Itching 60 (11) # (-- ) # (-- )
Dryness 105 (19) 34 (23) 29 (18)
Erythema 86 (16) 10 ( 7 ) 22 (14)
Oiliness/Oily Skin 8 ( 1 ) 26 (18) 12*(10)
Peeling 61 (11) # (-- ) 11 ( 7 )
# not recorded
* of 126 subjects

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.

Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).

Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.